-
Success of GLP-1 receptor agonists in kidney disease halts FLOW trial early
Diabetes is the leading cause of chronic kidney disease. Glucagon-like peptide-1 (GLP-1) receptor agonists hold promise as an effective new therapy to combat this condition. Richard E. Pratley, MD, and other researchers will share new data on the renal and cardiovascular benefits of GLP-1 receptor agonists.
-
SELECT trial demonstrates semaglutide benefits beyond reduction of cardiovascular events
Although SELECT was not designed as a diabetes prevention study, investigators have found clinical benefits for these patients. Using a glucagon-like peptide-1 (GLP-1) receptor agonist can reduce risk of progressing to diabetes, for example, said Steven E. Kahn, MB, ChB, one of the panelists in a symposium that will examine SELECT trial results.
-
ATTEMPT trial reveals SGLT2 inhibitors’ impact on adolescent and youth type 1 diabetes
Farid Mahmud, MD, will present the renal and glycemic outcomes from a trial designed to assess the impact of a sodium-glucose cotransporter-2 (SGLT2) inhibitor in combination with insulin therapy. The session will include insights on adjunctive therapy in youth with type 1 diabetes and patient perspectives on disease management.
-
Symposium to address the real costs of disparities in diabetes care and how to overcome ongoing inequities
Collaboration among providers is one key element in closing gaps in access to care and improving outcomes for people living with diabetes, says Osagie Ebekozien, MD, MPH, CPHQ, one of the panelists who will discuss cost and quality considerations for patient care.
-
Researchers to discuss benefits of intermittent fasting in diabetes
Intermittent fasting—focusing on when you eat instead of what you eat—may offer benefits for glycemic control, weight loss, polycystic ovarian syndrome, and diabetes progression. Panelist Lisa S. Chow, MD, MS, will focus on the role of time-restricted eating in diabetes treatment.
-
Ask the Expert session to analyze evolutions in diabetes care spurred by AI
Artificial intelligence (AI) is shaping the future of diabetes data science, the structure of multidisciplinary care teams, and the devices used to manage diabetes. Boris Kovatchev, PhD, and other experts will hold a multifaceted discussion analyzing several applications of AI in the clinical setting.
-
Access to new antiobesity drugs illustrates ongoing pharmacoequity challenges
Experts including Utibe Essien, MD, MPH, and Alison Sexton Ward, PhD, will address the goal of ensuring that all patients have equal and affordable access to the highest quality medication to manage their health.
-
Symposium to show how diabetes both causes and complicates organ transplantation
Archana R. Sadhu, MD, FACE, and other panelists will explain how diabetes and organ transplantation can increase risks for cardiovascular disease and other metabolic complications.